Table 1.

Demographic, clinical, and laboratory characteristics of 82,958 MHD patients, including 15,859 MHD patients who had available cholesterol data and an additional subset of 1418 who had LDL measurementsa

CharacteristicAll MHD PatientsLipid MeasuredP
CholesterolLDL
Age (yr; %)61 ± 1661 ± 1561 ± 160.01
    >65434449<0.001
Gender (% women)4647450.2
Diabetes (%)4549470.01
Race and ethnicity (%)<0.001
    white403739
    Black323131
    Asian 3 2 2
    Hispanic151918
Time on dialysis <6 mo (%)292327<0.001
Medicare as primary insurance (%)657062<0.001
Standardized mortality ratio0.80 ± 0.280.76 ± 0.240.71 ± 0.21<0.001
Cohort time (mo)480 ± 384460 ± 334444 ± 3260.06
BMI (kg/m2)26.5 ± 6.126.9 ± 6.426.6 ± 6.10.08
nPCR or nPNA (g/kg per d)0.98 ± 0.241.01 ± 0.251.03 ± 0.250.05
Serum total cholesterol (mg/dl)159 ± 43156 ± 41153 ± 410.008
    LDL (mg/dl)74 ± 3075 ± 3275 ± 32NA
    HDL (mg/dl)47 ± 1447 ± 1546 ± 140.33
    triglyceride (mg/dl)166 ± 114162 ± 109163 ± 1010.85
    albumin (g/dl)3.73 ± 0.443.81 ± 0.413.83 ± 0.400.03
    creatinine (mg/dl)8.7 ± 3.28.8 ± 3.19.0 ± 3.30.001
    bicarbonate21.8 ± 2.821.6 ± 3.121.1 ± 3.1<0.001
    ferritin (ng/ml)569 ± 465568 ± 458543 ± 4240.03
    TIBC (mg/dl)202 ± 42 204 ± 42 205 ± 43 0.4
Blood hemoglobin (g/dl)12.01 ± 1.32 12.13 ± 1.28 12.08 ± 1.25 0.1
    WBC count (per fl)7.4 ± 2.37.2 ± 2.27.2 ± 2.30.5
    lymphocyte (% of WBC)21 ± 8 21 ± 8 21 ± 8 0.3
Preexisting comorbidities (%)
    HIV (including AIDS) 2 2 20.6
    cancer 3 4 30.4
    CHF2126250.6
    ischemic heart disease1518190.3
    peripheral vascular disease 910120.06
    history of tobacco use 4 5 30.004
  • a P value compares those who had cholesterol data with the subset of patients who had available LDL measurements. BMI, body mass index; CHF, congestive heart failure; MHD, maintenance hemodialysis; NA, not applicable; nPCR, normalized protein catabolic rate; nPNA, normalized protein nitrogen appearance; TIBC, total iron-binding capacity; WBC, white blood cell.\